OSI, Merck deal

OSIP's Prosidion unit granted MRK a non-exclusive worldwide license to U.S. Patent No. 6,890,898, which covers the combination of a dipeptidyl peptidase-4 (DPP-4) inhibitor and another therapeutic to...